SCHEMBL23580686

SCHEMBL23580686

CC(C)(C)OC(=O)N1CC(O)C(C2CC2)(C(F)(F)F)C1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
HPGD P15428 1/20 0.38
RORC P51449 7/20 0.38
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RECQL P46063 1/20 0.37
EPHX1 P07099 1/20 0.37
DDB1 Q16531 2/20 0.36
CRBN Q96SW2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23580992 0.79 RORC (0.41) NR1H2CHRM2CHRM1CHRM3RORC
SCHEMBL30718602 0.78 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL17499855 0.78 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL16714648 0.78 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HPGD
Methane SCHEMBL28623117 0.77 NR1H2 (0.42) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL23608770 0.77 NR1H2 (0.39) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL22776027 0.76 NR1H2 (0.44) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL17081079 0.76 NR1H2 (0.44) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL17499914 0.76 NR1H2 (0.44) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL17499918 0.75 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 CN disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
EP-4081526-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-11-02 EP disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A NR1H2 1989/4885CHRM2 4606/4885CHRM1 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.